Navigation Links
Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
Date:3/5/2009

TUSTIN, Calif., March 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the third quarter of fiscal year 2009 on March 12, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the third quarter ended January 31, 2009 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 19, 2009 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manuf
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
3. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
6. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
9. Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
10. Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth
11. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... and radiotherapy at the same time could stop them ... published in Cancer Research * today (Wednesday). ... Manchester and funded by MedImmune, the global biologics research ... found that combining the two treatments helped the immune ... killed by the initial radiotherapy in mice with breast, ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... Randy Dotinga HealthDay Reporter ... unemployment rates climb, women tend to put the brakes on ... out to be a permanent choice, new research suggests. ... not to have a child during tough economic times. But, ... women will remain childless into their 40s and beyond. ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
Breaking Medicine News(10 mins):Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... CHICAGO, Aug. 21 Illinois U.S. Senate candidate Cheryle Jackson ... achieve the dual goals of containing costs and expanding access to ... , Jackson said that health care cooperatives are not ... national public plan that competes with the private insurance industry because ...
... ... Attract, Retain and Serve Health Insurance Consumers , ... Orlando, FL (Vocus) August 21, 2009 -- As the ... is making individual consumers become more involved in the health insurance decision-making process, as ...
... Angeles, London, New Delhi, Singapore and Washington DC (August 21, ... could benefit from a lighter touch but from a ... created a touchy-feely robot that detects tougher tumour tissue in ... human. The technique also minimises tissue damage. Surgeons have ...
... Brown adipose tissue (BAT) brown fat, which is found ... lead to new ways of preventing obesity. Studies have ... obesity. Therefore, promoting BAT function could prevent or reduce obesity ... Symonds, Professor of Developmental Physiology in the School of Clincal ...
... Aug. 21 President Obama,s Council of Advisors on Science and ... reform, energy and the environment -- and the President is listening. ... little about our healthcare system that does not concern us," said ... A primary care physician, he noted that less than 20 ...
... and good rapport with physician is key, , FRIDAY, ... acid reflux is one of the most common complaints ... appear to work best to ease patients, suffering. , ... -- formally called gastroesophageal reflux disease (GERD) -- typically ...
Cached Medicine News:Health News:U.S. Senate Candidate Cheryle Jackson: 'Public Option Critical to Real Health Care Reform' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 3Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 4Health News:Robot's gentle touch aids delicate cancer surgery 2Health News:Robot's gentle touch aids delicate cancer surgery 3Health News:Daylight could help control our weight 2Health News:PCAST Members Advise President on Future of Healthcare, Energy 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 3
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: